Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)
CTR20255070Phase 2Active
- Sponsor
- YuanYi Biotech
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of claseprubart in multifocal motor neuropathy (MMN), sponsored by YuanYi Biotech. Started Mar 2025; status: active.
02
Drugs
claseprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on CTR20255070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255070.